Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Cash and cash equivalents consisted of the following (in thousands):

	March 31, 2017		December 31, 2016
Cash	$	86,679	$	79,239
Money market funds		83,919		94,543
Total cash and cash equivalents	$	170,598	$	173,782

Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments

All investments are classified as available-for-sale. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s available-for-sale investments by major investments type are summarized in the tables below (in thousands):

	March 31, 2017
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	101,898	$	147	$	(41	)	$	102,004
Certificate of deposits		1,036		—		—			1,036
Bond and mutual funds		22,704		205		(175	)		22,734
Equity investments		126		79		—			205
Total investments	$	125,764	$	431	$	(216	)	$	125,979

	December 31, 2016
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Corporate bonds	$	126,550	$	182	$	(49	)	$	126,683
Certificate of deposits		1,037		—		—			1,037
Bond and mutual funds		22,305		157		—			22,462
Equity investments		125		100		—			225
Total investments	$	150,017	$	439	$	(49	)	$	150,407

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2017		December 31, 2016
Preclinical and clinical trial accruals	$	31,052	$	29,550
Payroll and related accruals		9,050		14,232
Professional services		1,434		1,252
Other		7,643		5,880
Total accrued liabilities	$	49,179	$	50,914